Sanofi has announced that Lyxumia® (lixisenatide), a once-daily GLP-1 receptor agonist under development for type 2 diabetes, achieved its primary efficacy endpoint of significant HbA1c reduction vs.
USMLE exams, Step 1 and Step 2 are well known and necessary components of your medical education and the Office of Student Affairs seeks to ensure that all BCM students are equipped with the necessary ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback